Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız:
http://hdl.handle.net/11452/33016
Başlık: | Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS) |
Yazarlar: | Chen, Chung-Hwan Elsalmawy, Abdulaziz H. Ish-Shalom, Sophia Lim, Seung-Jae Ai-Ali, Nadia S. Cunha-Borges, Joao L. Yang, Huilin Casas, Noemi Altan, Lale Moll, Thomas Gurbuz, Sirel Brnabic, Alan J. M. Burge, Russel T. Marin, Fernando Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/Fizik Tedavi ve Rehabilitasyon Bölümü. Altan, Lale AAH-1652-2021 6603281363 |
Anahtar kelimeler: | General & internal medicine Research & experimental medicine Fractures Observational study Osteoporosis Teriparatide Questionnaire-physical function Parathyroıd-hormone 1-34 Quality-of-life Opaq-pf Prevention Guidelines |
Yayın Tarihi: | 3-Haz-2019 |
Yayıncı: | Taylor |
Atıf: | Chen, C.H. vd. (2019). ''Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)''. Current Medical Research and Opinion, 35(6), 1041-1049. |
Özet: | Objective: To describe the study design and baseline patient characteristics of the Asia and Latin America Fracture Observational Study (ALAFOS) to better understand the profile of patients receiving teriparatide during the course of routine clinical practice in Asia, Latin America, the Middle East and Russia. Methods: Prospective, observational, non-interventional study in postmenopausal women with osteoporosis who are prescribed teriparatide for up to 24 months, according to local medical standards, with a 12 month post-treatment follow-up. Measures: Demographics, risk factors for osteoporosis and fractures, history of fracture, prior osteoporosis medications, comorbidities, physical function, back pain and quality of life (QoL). Results: In total 3031 postmenopausal women (mean age 72.5 years) recruited at 152 sites in 20 countries were analyzed; 62.9% had a history of fragility fracture after age 40 (33.0% of patients with spinal, 14.2% with hip fractures). The mean (SD) bone mineral density T-scores at baseline were -3.06 (1.40) and -2.60 (1.05) at the lumbar spine and femoral neck, respectively. At entry, 43.7% of patients were naive to prior osteoporosis treatments; 40.5% of patients reported >= 1 fall in the past year. The median (Q1; Q3) EuroQoL Visual Analog Scale (EQ-VAS) for perceived overall health status was 60 (50; 80). The mean (SD) worst back pain Numeric Rating Scale in the last 24 hours was 4.6 (3.3). Conclusions: Our data indicates that patients who were prescribed teriparatide in the ALAFOS participant countries had severe osteoporosis, high prevalence of fractures, disabling back pain and poor QoL. The frequency of patients receiving prior osteoporosis medications was lower than in previous observational studies conducted in other locations. |
URI: | https://doi.org/10.1080/03007995.2018.1552576 https://www.tandfonline.com/doi/full/10.1080/03007995.2018.1552576 http://hdl.handle.net/11452/33016 |
ISSN: | 0300-7995 1473-4877 |
Koleksiyonlarda Görünür: | Scopus Web of Science |
Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.